Analysis of Profitability Ratios
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
IQVIA Holdings Inc., profitability ratios
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | IQVIA Holdings Inc. gross profit margin ratio deteriorated from 2020 to 2021 but then improved from 2021 to 2022 exceeding 2020 level. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | IQVIA Holdings Inc. operating profit margin ratio improved from 2020 to 2021 and from 2021 to 2022. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | IQVIA Holdings Inc. net profit margin ratio improved from 2020 to 2021 and from 2021 to 2022. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | IQVIA Holdings Inc. ROE improved from 2020 to 2021 and from 2021 to 2022. |
| ROA | A profitability ratio calculated as net income divided by total assets. | IQVIA Holdings Inc. ROA improved from 2020 to 2021 and from 2021 to 2022. |
Gross Profit Margin
IQVIA Holdings Inc., gross profit margin calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Gross profit | 5,028) | 4,641) | 3,859) | 3,788) | 3,666) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Profitability Ratio | ||||||
| Gross profit margin1 | 34.89% | 33.45% | 33.97% | 34.16% | 35.21% | |
| Benchmarks | ||||||
| Gross Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 70.00% | 68.96% | 66.41% | 77.64% | — | |
| Amgen Inc. | 74.17% | 73.44% | 74.59% | 80.38% | — | |
| Bristol-Myers Squibb Co. | 78.04% | 78.57% | 72.31% | 69.10% | — | |
| Danaher Corp. | 60.21% | 60.95% | 55.98% | 55.74% | — | |
| Eli Lilly & Co. | 76.77% | 74.18% | 77.66% | 78.85% | — | |
| Gilead Sciences Inc. | 79.03% | 75.56% | 81.23% | 78.86% | — | |
| Johnson & Johnson | 67.26% | 68.16% | 65.58% | 66.42% | — | |
| Merck & Co. Inc. | 70.63% | 72.02% | 67.74% | 69.87% | — | |
| Moderna Inc. | 70.62% | 85.19% | 96.03% | — | — | |
| Pfizer Inc. | 65.77% | 62.08% | 79.26% | 80.25% | — | |
| Regeneron Pharmaceuticals Inc. | 87.18% | 84.83% | 86.82% | 90.05% | — | |
| Thermo Fisher Scientific Inc. | 42.24% | 50.08% | 49.67% | 44.35% | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Revenues
= 100 × 5,028 ÷ 14,410 = 34.89%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | IQVIA Holdings Inc. gross profit margin ratio deteriorated from 2020 to 2021 but then improved from 2021 to 2022 exceeding 2020 level. |
Operating Profit Margin
IQVIA Holdings Inc., operating profit margin calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Income from operations | 1,799) | 1,393) | 731) | 777) | 741) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Profitability Ratio | ||||||
| Operating profit margin1 | 12.48% | 10.04% | 6.44% | 7.01% | 7.12% | |
| Benchmarks | ||||||
| Operating Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 31.21% | 31.89% | 24.81% | 39.03% | — | |
| Amgen Inc. | 38.57% | 31.44% | 37.70% | 43.57% | — | |
| Bristol-Myers Squibb Co. | 17.96% | 15.91% | -21.60% | 22.62% | — | |
| Danaher Corp. | 27.61% | 25.35% | 18.99% | 18.25% | — | |
| Eli Lilly & Co. | 24.97% | 22.45% | 24.69% | 22.29% | — | |
| Gilead Sciences Inc. | 27.17% | 36.72% | 16.72% | 19.38% | — | |
| Johnson & Johnson | 24.63% | 24.95% | 23.60% | 24.15% | — | |
| Merck & Co. Inc. | 30.27% | 25.74% | 16.47% | 24.77% | — | |
| Moderna Inc. | 51.10% | 75.22% | -381.82% | — | — | |
| Pfizer Inc. | 34.83% | 23.91% | 19.47% | 25.46% | — | |
| Regeneron Pharmaceuticals Inc. | 38.93% | 55.67% | 42.09% | 28.10% | — | |
| Thermo Fisher Scientific Inc. | 18.69% | 25.57% | 24.19% | 17.99% | — | |
| Operating Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 28.92% | 28.39% | 18.09% | 25.68% | — | |
| Operating Profit Margin, Industry | ||||||
| Health Care | 13.52% | 13.78% | 10.30% | 12.31% | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Operating profit margin = 100 × Income from operations ÷ Revenues
= 100 × 1,799 ÷ 14,410 = 12.48%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | IQVIA Holdings Inc. operating profit margin ratio improved from 2020 to 2021 and from 2021 to 2022. |
Net Profit Margin
IQVIA Holdings Inc., net profit margin calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to IQVIA Holdings Inc. | 1,091) | 966) | 279) | 191) | 259) | |
| Revenues | 14,410) | 13,874) | 11,359) | 11,088) | 10,412) | |
| Profitability Ratio | ||||||
| Net profit margin1 | 7.57% | 6.96% | 2.46% | 1.72% | 2.49% | |
| Benchmarks | ||||||
| Net Profit Margin, Competitors2 | ||||||
| AbbVie Inc. | 20.39% | 20.54% | 10.08% | 23.69% | — | |
| Amgen Inc. | 26.42% | 24.25% | 29.97% | 35.32% | — | |
| Bristol-Myers Squibb Co. | 13.71% | 15.08% | -21.20% | 13.15% | — | |
| Danaher Corp. | 22.91% | 21.84% | 16.36% | 16.80% | — | |
| Eli Lilly & Co. | 21.88% | 19.71% | 25.24% | 37.27% | — | |
| Gilead Sciences Inc. | 17.02% | 23.05% | 0.51% | 24.35% | — | |
| Johnson & Johnson | 18.90% | 22.26% | 17.82% | 18.42% | — | |
| Merck & Co. Inc. | 24.49% | 26.79% | 14.72% | 21.01% | — | |
| Moderna Inc. | 45.36% | 69.04% | -373.77% | — | — | |
| Pfizer Inc. | 31.27% | 27.04% | 22.95% | 31.45% | — | |
| Regeneron Pharmaceuticals Inc. | 35.64% | 50.25% | 41.35% | 26.91% | — | |
| Thermo Fisher Scientific Inc. | 15.47% | 19.70% | 19.79% | 14.47% | — | |
| Net Profit Margin, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 23.12% | 24.90% | 13.44% | 23.02% | — | |
| Net Profit Margin, Industry | ||||||
| Health Care | 10.55% | 11.48% | 7.64% | 10.09% | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Net profit margin = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Revenues
= 100 × 1,091 ÷ 14,410 = 7.57%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | IQVIA Holdings Inc. net profit margin ratio improved from 2020 to 2021 and from 2021 to 2022. |
Return on Equity (ROE)
IQVIA Holdings Inc., ROE calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to IQVIA Holdings Inc. | 1,091) | 966) | 279) | 191) | 259) | |
| Equity attributable to IQVIA Holdings Inc.’s stockholders | 5,765) | 6,042) | 6,001) | 6,003) | 6,714) | |
| Profitability Ratio | ||||||
| ROE1 | 18.92% | 15.99% | 4.65% | 3.18% | 3.86% | |
| Benchmarks | ||||||
| ROE, Competitors2 | ||||||
| AbbVie Inc. | 68.60% | 74.91% | 35.30% | — | — | |
| Amgen Inc. | 178.97% | 87.96% | 77.20% | 81.07% | — | |
| Bristol-Myers Squibb Co. | 20.37% | 19.46% | -23.84% | 6.66% | — | |
| Danaher Corp. | 14.39% | 14.24% | 9.17% | 9.94% | — | |
| Eli Lilly & Co. | 58.64% | 62.16% | 109.79% | 319.09% | — | |
| Gilead Sciences Inc. | 21.62% | 29.55% | 0.68% | 23.91% | — | |
| Johnson & Johnson | 23.36% | 28.20% | 23.25% | 25.42% | — | |
| Merck & Co. Inc. | 31.57% | 34.17% | 27.91% | 37.99% | — | |
| Moderna Inc. | 43.73% | 86.26% | -29.17% | -43.75% | — | |
| Pfizer Inc. | 32.79% | 28.47% | 15.21% | 25.77% | — | |
| Regeneron Pharmaceuticals Inc. | 19.14% | 43.03% | 31.86% | 19.08% | — | |
| Thermo Fisher Scientific Inc. | 15.80% | 18.94% | 18.47% | 12.45% | — | |
| ROE, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 28.81% | 31.93% | 16.48% | 27.56% | — | |
| ROE, Industry | ||||||
| Health Care | 22.88% | 24.08% | 15.82% | 20.90% | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
ROE = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 100 × 1,091 ÷ 5,765 = 18.92%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | IQVIA Holdings Inc. ROE improved from 2020 to 2021 and from 2021 to 2022. |
Return on Assets (ROA)
IQVIA Holdings Inc., ROA calculation, comparison to benchmarks
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net income attributable to IQVIA Holdings Inc. | 1,091) | 966) | 279) | 191) | 259) | |
| Total assets | 25,337) | 24,689) | 24,564) | 23,251) | 22,549) | |
| Profitability Ratio | ||||||
| ROA1 | 4.31% | 3.91% | 1.14% | 0.82% | 1.15% | |
| Benchmarks | ||||||
| ROA, Competitors2 | ||||||
| AbbVie Inc. | 8.53% | 7.88% | 3.07% | 8.84% | — | |
| Amgen Inc. | 10.06% | 9.63% | 11.54% | 13.13% | — | |
| Bristol-Myers Squibb Co. | 6.53% | 6.40% | -7.61% | 2.65% | — | |
| Danaher Corp. | 8.55% | 7.73% | 4.79% | 4.85% | — | |
| Eli Lilly & Co. | 12.62% | 11.44% | 13.28% | 21.17% | — | |
| Gilead Sciences Inc. | 7.27% | 9.16% | 0.18% | 8.74% | — | |
| Johnson & Johnson | 9.57% | 11.47% | 8.41% | 9.59% | — | |
| Merck & Co. Inc. | 13.30% | 12.35% | 7.72% | 11.66% | — | |
| Moderna Inc. | 32.34% | 49.46% | -10.18% | -32.34% | — | |
| Pfizer Inc. | 15.91% | 12.11% | 6.23% | 9.72% | — | |
| Regeneron Pharmaceuticals Inc. | 14.85% | 31.75% | 20.47% | 14.29% | — | |
| Thermo Fisher Scientific Inc. | 7.15% | 8.12% | 9.23% | 6.33% | — | |
| ROA, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 11.04% | 11.19% | 5.14% | 8.90% | — | |
| ROA, Industry | ||||||
| Health Care | 8.60% | 8.69% | 5.36% | 7.15% | — | |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
ROA = 100 × Net income attributable to IQVIA Holdings Inc. ÷ Total assets
= 100 × 1,091 ÷ 25,337 = 4.31%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | IQVIA Holdings Inc. ROA improved from 2020 to 2021 and from 2021 to 2022. |